302 related articles for article (PubMed ID: 32057100)
21. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
Vrooman LM; Supko JG; Neuberg DS; Asselin BL; Athale UH; Clavell L; Kelly KM; Laverdière C; Michon B; Schorin M; Cohen HJ; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2010 Feb; 54(2):199-205. PubMed ID: 19672973
[TBL] [Abstract][Full Text] [Related]
22. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
[TBL] [Abstract][Full Text] [Related]
23. Comparative pharmacokinetic studies of three asparaginase preparations.
Asselin BL; Whitin JC; Coppola DJ; Rupp IP; Sallan SE; Cohen HJ
J Clin Oncol; 1993 Sep; 11(9):1780-6. PubMed ID: 8355045
[TBL] [Abstract][Full Text] [Related]
24. The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
Alrazzak M; Beaupin LK; Kinyoun P; Barth M
J Pediatr Hematol Oncol; 2016 Jan; 38(1):e16-20. PubMed ID: 26558809
[TBL] [Abstract][Full Text] [Related]
25. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries.
Albertsen BK; Schrøder H; Jakobsen P; Müller HJ; Carlsen NT; Schmiegelow K
Br J Clin Pharmacol; 2001 Oct; 52(4):433-7. PubMed ID: 11678787
[TBL] [Abstract][Full Text] [Related]
26. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
Billett AL; Carls A; Gelber RD; Sallan SE
Cancer; 1992 Jul; 70(1):201-6. PubMed ID: 1606543
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols.
Vieira Pinheiro JP; Ahlke E; Nowak-Göttl U; Hempel G; Müller HJ; Lümkemann K; Schrappe M; Rath B; Fleischhack G; Mann G; Boos J
Br J Haematol; 1999 Feb; 104(2):313-20. PubMed ID: 10050714
[TBL] [Abstract][Full Text] [Related]
29. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
Boos J; Werber G; Ahlke E; Schulze-Westhoff P; Nowak-Göttl U; Würthwein G; Verspohl EJ; Ritter J; Jürgens H
Eur J Cancer; 1996 Aug; 32A(9):1544-50. PubMed ID: 8911116
[TBL] [Abstract][Full Text] [Related]
30. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.
Maese L; Loh ML; Choi MR; Lin T; Aoki E; Zanette M; Agarwal S; Iannone R; Silverman JA; Silverman LB; Raetz EA; Rau RE
Blood; 2023 Feb; 141(7):704-712. PubMed ID: 36108304
[TBL] [Abstract][Full Text] [Related]
31. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
[TBL] [Abstract][Full Text] [Related]
32. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Vrooman LM; Stevenson KE; Supko JG; O'Brien J; Dahlberg SE; Asselin BL; Athale UH; Clavell LA; Kelly KM; Kutok JL; Laverdière C; Lipshultz SE; Michon B; Schorin M; Relling MV; Cohen HJ; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2013 Mar; 31(9):1202-10. PubMed ID: 23358966
[TBL] [Abstract][Full Text] [Related]
33. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Pieters R; Hunger SP; Boos J; Rizzari C; Silverman L; Baruchel A; Goekbuget N; Schrappe M; Pui CH
Cancer; 2011 Jan; 117(2):238-49. PubMed ID: 20824725
[TBL] [Abstract][Full Text] [Related]
34. Asparaginase: an old drug with new questions.
Cecconello DK; Magalhães MR; Werlang ICR; Lee MLM; Michalowski MB; Daudt LE
Hematol Transfus Cell Ther; 2020; 42(3):275-282. PubMed ID: 31801703
[TBL] [Abstract][Full Text] [Related]
35. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.
Armstrong JK; Hempel G; Koling S; Chan LS; Fisher T; Meiselman HJ; Garratty G
Cancer; 2007 Jul; 110(1):103-11. PubMed ID: 17516438
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration.
Albertsen BK; Jakobsen P; Schrøder H; Schmiegelow K; Carlsen NT
Cancer Chemother Pharmacol; 2001 Jul; 48(1):77-82. PubMed ID: 11488528
[TBL] [Abstract][Full Text] [Related]
37. Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
Ogawa C; Taguchi F; Goto H; Koh K; Tomizawa D; Ohara A; Manabe A
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244643
[TBL] [Abstract][Full Text] [Related]
38. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
[TBL] [Abstract][Full Text] [Related]
39. Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial.
Schrey D; Speitel K; Lanvers-Kaminsky C; Gerss J; Möricke A; Boos J
Pediatr Blood Cancer; 2011 Sep; 57(3):378-84. PubMed ID: 21337682
[TBL] [Abstract][Full Text] [Related]
40. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
